poliomyel
caus
polio
viru
rna
viru
colon
gastroenter
tract
may
lead
acut
viral
infecti
diseas
spread
person
person
primarili
via
fecalor
rout
world
health
assembl
resolv
global
erad
poliomyel
polio
initi
object
end
polio
proven
difficult
origin
envis
polio
still
exist
countri
afghanistan
nigeria
pakistan
howev
due
great
effort
number
polio
case
decreas
level
full
erad
within
decad
two
realist
goal
two
vaccin
exist
polio
inactiv
polio
vaccin
ipv
trival
live
oral
polio
viru
topv
topv
attenu
sabin
strain
polioviru
type
vaccin
choic
polio
vaccin
countri
induc
system
intestin
immun
immun
boost
immun
close
contact
secondari
spread
inexpens
easi
administ
howev
one
problem
opv
rare
occas
opv
caus
vaccineassoci
paralyt
poliomyel
vapp
andor
revert
neurovirul
form
polioviru
believ
transmiss
virul
wild
poliovirus
therefor
step
taken
discontinu
opv
vaccin
polio
render
ipv
realist
polio
vaccin
posterad
era
opv
withdrawn
sever
challeng
concern
ipv
dealt
one
challeng
high
purchas
cost
ipv
potenti
lead
limit
suppli
ipv
mani
countri
anoth
challeng
concern
immun
induc
ipv
achiev
intestin
immun
vaccin
ipv
protect
vaccin
recipi
paralysi
compar
opv
provid
less
protect
reinfect
furthermor
ipv
reduc
fecal
excret
follow
reinfect
much
opv
provid
weaker
intestin
immun
howev
studi
demonstr
ipv
induc
intestin
immun
one
way
reduc
cost
vaccin
use
adjuv
field
pandem
influenza
vaccin
use
adjuv
permit
dose
reduct
increas
avail
reduc
cost
vaccin
therefor
specul
adjuv
vaccin
formul
ipv
would
reduc
cost
also
increas
number
avail
ipv
dose
worldwid
support
recent
shown
potenc
sabin
inactiv
polio
vaccin
increas
adjuv
aluminium
hydroxid
cpg
novel
adjuv
compos
cation
liposom
dda
dimethyldioctadecylammonium
stabil
synthet
immunomodul
tdb
trehalos
proven
enhanc
humor
cellmedi
memori
immun
respons
number
differ
experiment
vaccin
candid
preclin
model
furthermor
alreadi
test
three
phasei
trial
excel
safeti
immunogen
profil
eag
person
commun
addit
also
found
provid
dosespar
use
combin
trival
influenza
split
vaccin
ferret
therefor
test
suitabl
adjuv
induc
protect
immun
infect
polio
viru
well
known
mucos
immun
achiev
vaccin
mucos
site
question
vaccin
given
intramuscular
rout
primarili
produc
system
immun
mucos
site
isol
immunolog
site
prime
immun
respons
one
mucos
site
may
also
induc
protect
anoth
mucos
site
although
skin
tradit
regard
mucos
site
previou
result
group
nevertheless
indic
intraderm
administr
may
confer
intestinalmucos
protect
addit
intraderm
administr
wellknown
deliveri
rout
nonadjuv
ipv
vaccin
human
shown
safe
deliveri
rout
advers
effect
therefor
decid
test
differ
vaccin
strategi
involv
intraderm
intramuscular
administr
adjuv
ipv
order
achiev
intestin
immun
ipv
vaccin
taken
togeth
aim
present
work
twofold
achiev
dose
spare
measur
neutral
titer
induc
intestin
immun
ipv
vaccin
experi
conduct
accord
regul
set
forward
danish
ministri
justic
anim
protect
committe
danish
anim
experi
inspector
permit
januari
complianc
european
commun
direct
us
associ
laboratori
anim
care
recommend
care
use
laboratori
anim
experi
approv
staten
serum
institut
iacuc
method
sacrific
cervic
disloc
studi
perform
femal
mice
harlan
scandinavia
anim
hous
appropri
anim
facil
staten
serum
institut
ipv
vaccin
appli
throughout
studi
commerci
gmp
grade
materi
manufactur
staten
serum
institut
ssi
trival
ipv
formul
ratio
polio
viru
type
brunhild
strain
type
type
saukett
respect
trival
ipv
vaccin
studi
alway
formul
trival
stock
ipv
tp
duml
individu
concentr
bulk
materi
monoval
ipv
store
buffer
dilut
ipv
respect
concentr
use
immun
perform
mm
tri
buffer
ph
trival
stock
ipv
tp
duml
dilut
appropri
concentr
ad
ipv
stock
solut
given
volum
buffer
indic
dosag
unit
experi
correspond
antigen
unit
vaccin
trival
unless
otherwis
state
adjuv
suspens
manufactur
two
lipid
concentr
mgml
dda
tdb
mgml
respect
dda
tdb
manufactur
niel
clausonkaa
farum
denmark
brief
lipid
film
ml
form
dissolv
dda
g
ml
chloroformmethanol
vv
mix
tdb
g
dissolv
ml
chloroformmethanol
vv
ml
bluecap
flask
organ
solvent
remov
use
gentl
stream
form
thin
lipid
film
bottom
flask
lipid
film
dri
vacuum
night
remov
trace
amount
organ
solvent
lipid
film
hydrat
ml
mm
trisbuff
ph
high
speed
highshear
mix
heidolph
silent
crusher
minut
adjuv
store
use
formul
procedur
appli
smaller
amount
dda
tdb
g
respect
ml
adjuv
store
use
vaccin
formul
addmix
vv
ipv
solut
solut
moder
stir
use
magnet
stir
bar
vaccin
rest
minut
allow
adsorpt
ipv
cation
liposom
vaccin
intend
mice
appli
order
formul
mous
dose
dose
volum
im
vaccin
vv
mix
ipv
antigen
solut
appli
formul
vaccin
physicchem
analys
vaccin
formul
perform
laf
unit
vaccin
store
use
manufactur
adjuv
ipv
vaccin
vaccin
perform
laf
unit
final
concentr
mous
studi
ug
ddatdb
mice
immun
two
three
time
twoweek
interv
intramuscularli
im
caudal
thigh
ipv
ipv
formul
altern
mice
immun
via
intraderm
id
back
rout
ipv
dose
use
experi
indic
figur
two
week
second
third
vaccin
immun
respons
ipv
analyz
experi
immun
respons
also
analyz
week
second
vaccin
lymphocyt
cultur
purifi
describ
previous
briefli
pbmc
purifi
densiti
gradient
splenocyt
cultur
obtain
passag
cell
strainer
bd
pharmingen
ipv
stimul
use
supernat
triplic
cultur
cell
per
well
harvest
cultur
h
incub
investig
cytokin
sandwich
elisa
use
determin
concentr
cultur
supernat
previous
describ
altern
cytokin
analyz
multiplex
cytokin
assay
cytokin
assay
singleplex
assay
meso
scale
discoveri
gaithersburg
md
perform
accord
manufactur
instruct
plate
read
sector
imag
system
calcul
cytokin
concentr
unknown
sampl
determin
logist
nonlinear
regress
analysi
standard
curv
ipv
dantigen
quantifi
use
sandwich
elisa
du
elisa
detect
dunit
activ
ipv
brief
immuno
plate
maxisorp
nunc
coat
polyclon
antibodi
rais
rabbit
immun
inactiv
polioviru
type
brunhild
strain
type
mef
strain
type
saukett
strain
polio
type
dilut
pb
phenolr
hour
humidifi
atmospher
room
temperatur
wash
block
well
standard
sampl
dilut
pb
contain
nacl
kcl
triton
bsa
phenolr
ad
well
follow
overnight
incub
humidifi
atmospher
well
wash
subsequ
hrpconjug
polyclon
antibodi
polio
type
dilut
fb
phenolr
ad
well
incub
hour
humidifi
atmospher
room
temperatur
well
wash
opd
substrat
ad
follow
minut
incub
period
dark
room
temperatur
reaction
stop
addit
plate
read
od
nm
nonspecif
absorpt
nm
subtract
briefli
neutral
antibodi
titer
three
polioviru
serotyp
measur
use
brunhild
saukett
viru
stock
vero
cell
dilut
sera
made
duplic
start
serial
dilut
approxim
cell
cultur
infecti
dose
polioviru
type
ad
well
well
plate
incub
hour
till
next
day
vero
cell
prepar
cell
suspens
cellsml
ad
well
contain
polio
virusserum
mixtur
plate
incub
day
well
show
neutralizingcytopathogen
activ
record
result
singl
dilut
seri
given
time
lowest
dilut
factor
dead
verocel
final
titr
calcul
geometr
mean
result
two
independ
dilut
seri
sampl
test
triplic
use
standard
microneutr
assay
antibodi
polioviru
type
accord
establish
protocol
global
polio
special
laboratori
center
diseas
control
prevent
cdc
briefli
polioviru
serotyp
twofold
serial
dilut
serum
combin
preincub
hour
addit
c
cell
incub
day
plate
stain
crystal
violet
cell
viabil
measur
optic
densiti
spectrophotomet
specimen
run
triplic
parallel
specimen
one
studi
subject
test
assay
run
neutral
titer
estim
method
report
reciproc
calcul
endpoint
run
contain
multipl
replic
refer
antiserum
pool
start
dilut
monitor
perform
variat
serum
sampl
consid
posit
antibodi
present
dilut
specimen
antibodi
titer
consid
seroneg
specimen
titer
consid
seroposit
mice
bled
collect
serum
follow
vaccin
maxisorp
micro
titer
plate
nunc
maxisorp
roskild
denmark
coat
ipv
tp
trival
inactiv
polio
viru
see
materi
method
ipv
type
ugml
pb
night
free
bind
site
block
skim
milk
pb
individu
mous
sera
analyz
duplic
fivefold
dilut
pb
contain
bovin
serum
albumin
start
dilut
horseradish
peroxidas
hrp
conjug
secondari
antibodi
rabbit
antimous
igg
iga
zyme
dilut
pb
bovin
serum
albumin
ad
h
incub
antigenspecif
antibodi
detect
tmb
substrat
describ
manufactur
kementec
copenhagen
denmark
stop
reaction
ul
n
ad
optic
densiti
od
measur
nm
absorb
valu
plot
function
reciproc
dilut
serum
sampl
fecal
pellet
collect
mice
two
week
follow
immun
mice
place
individu
cage
fresh
fecal
pellet
pellet
per
mous
collect
microfug
tube
contain
icecold
buffer
pb
soybean
trypsin
inhibitor
sigma
mgml
bovin
serum
albumin
bsa
wv
ethylenediaminetetraacet
acid
edta
mm
glycerol
vv
phenylmethylsulfonylfluorid
pmsf
mm
fecal
pellet
broken
form
suspens
incub
ice
hour
incub
fecal
pellet
solut
clarifi
centrifug
g
minut
supernat
transfer
microfug
tube
block
overnight
pb
contain
wv
bsa
supernat
frozen
analys
later
date
elisa
zaverag
diamet
zavg
liposom
determin
dynam
light
scatter
use
photon
correl
spectroscopi
pc
techniqu
measur
perform
use
malvern
nanoz
malvern
instrument
worcestershir
uk
equip
nm
laser
detect
optic
malvern
dt
v
softwar
use
data
acquisit
analysi
nanospheretm
size
standard
nm
duke
scientif
corp
duke
nc
use
verifi
perform
instrument
sampl
dilut
mm
trisbuff
ph
achiev
optim
vesicl
concentr
surfac
charg
vesicl
measur
indirectli
via
analysi
zetapotenti
use
malvern
nanoz
use
monomod
analysi
model
malvern
instrument
worcestershir
uk
dilut
milliq
water
signific
differ
immun
respons
measur
elisa
differ
neutral
titer
evalu
use
oneway
anova
tukey
multipl
comparison
test
multipl
comparison
valu
p
consid
signific
prism
version
softwar
graphpad
use
analysi
trival
ipv
analyz
without
trival
ipv
vaccin
formul
individu
materi
stock
ipv
tp
show
zavg
hydrodynam
diamet
nm
zavg
nm
accord
valu
polio
viru
size
determin
electron
microscopi
nm
indic
size
chang
upon
mix
three
ipv
monoval
trival
ipv
fig
furthermor
analysi
ipv
content
measur
dunit
activ
confirm
ipv
dunit
activ
maintain
mix
ipv
tp
fig
formul
particl
size
distribut
vaccin
zavg
dnm
found
nm
compar
nm
adjuv
indic
slight
increas
particl
size
ipv
bind
howev
within
accept
rang
also
measur
zeta
potenti
ipv
formul
fig
zeta
potenti
cation
mv
accord
previou
observ
monoval
ipv
show
slightli
neg
zeta
potenti
mv
wherea
adjuv
vaccin
show
posit
zeta
potenti
mv
therefor
ipv
vaccin
formul
bind
antigen
adjuv
electrostat
favor
measur
degre
associ
ipv
assum
sinc
suspens
cation
liposom
possibl
separ
vaccin
formul
vaccin
pellet
fraction
supernat
fraction
centrifug
subsequ
measur
ipv
du
elisa
fraction
ipv
bound
expect
locat
vaccin
pellet
three
vaccin
formul
evalu
bind
ipv
type
result
du
elisa
centrifug
sampl
shown
fig
ipv
found
supernat
fraction
three
formul
indic
ipv
serotyp
inde
bound
agreement
zeta
potenti
analysi
suggest
favor
interact
ipv
analyz
resuspend
vaccin
pellet
recoveri
rate
ipv
obtain
fig
reason
recoveri
less
probabl
due
steric
hindranc
caus
bind
detect
antibodi
ipv
du
elisa
ipv
howev
fulli
exclud
ipv
partli
inactiv
formul
next
examin
formul
mice
first
object
determin
abil
increas
neutral
antibodi
titer
polio
viru
blood
vaccin
anim
base
neutral
titer
obtain
mice
vaccin
rang
dose
du
dunit
du
data
shown
choos
du
full
mous
dose
du
dose
formul
adjuv
indic
dose
unit
experi
correspond
polio
viru
antigen
unit
thu
aim
achiev
time
dose
spare
mice
immun
du
ipv
lower
du
ipv
latter
without
mice
receiv
two
immun
space
two
week
neutral
antibodi
titer
determin
sera
two
week
last
immun
three
independ
experi
perform
two
assay
perform
staten
serum
institut
ssi
center
diseas
control
atlant
cdc
use
determin
neutral
titer
figur
repres
three
experi
wherea
individu
experi
shown
figur
result
show
induc
signific
increas
neutral
titer
serotyp
type
type
type
p
fig
neutral
titer
type
increas
transform
titer
du
ipv
group
ipv
group
neutral
titer
ipv
du
group
demonstr
dose
spare
effect
regard
type
titer
patter
seen
type
ipv
ipv
ipv
du
type
ipv
ipv
ipv
du
third
vaccin
led
signific
increas
neutral
titer
ipv
du
group
show
increas
type
type
type
fig
howev
two
vaccin
ipv
du
gave
neutral
titer
statist
differ
vaccin
ipv
although
trend
toward
higher
titer
type
ipv
alon
group
receiv
three
vaccin
fig
conclus
addit
adjuv
allow
time
dose
spare
moreov
two
vaccin
formul
vaccin
requir
achiev
neutral
titer
observ
three
vaccin
nonadjuv
ipv
also
examin
observ
increas
neutral
titer
correl
increas
antibodi
bind
titer
two
week
second
vaccin
sera
individu
mice
analyz
ipv
specif
antibodi
titer
measur
differ
ipv
specif
igg
isotyp
well
total
igg
level
three
viru
serotyp
ipv
du
group
observ
higher
igg
titer
sera
ipv
du
trival
ipv
serotyp
bind
titer
type
differ
ipv
du
group
importantli
titer
sera
mice
vaccin
ipv
du
higher
ipv
du
group
serotyp
least
high
ipv
du
group
fig
igg
isotyp
respons
bind
titer
observ
figur
also
examin
result
show
led
increas
antibodi
titer
igg
isotyp
fig
increas
igg
titer
observ
group
also
observ
week
follow
second
vaccin
demonstr
mere
transient
increas
fig
character
formul
also
analyz
cellular
respons
ipv
cellular
immun
toward
polio
viru
receiv
less
attent
due
compel
evid
humor
immun
import
effector
mechan
polio
howev
numer
exampl
cellular
immun
besid
effector
mechan
import
humor
immun
even
humor
immun
polio
viru
cellular
respons
character
analyz
cytokin
profil
ipvspecif
cell
induc
vaccin
ipv
alon
ipv
adjuv
pbmc
obtain
mice
vaccin
du
ipv
alon
ipv
du
two
five
week
follow
booster
vaccin
nonvaccin
mice
includ
control
thereaft
cell
stimul
vitro
ipv
hour
supernat
collect
multiplex
cytokin
analysi
week
post
vaccin
ipv
nonadjuv
group
multiplex
cytokin
analysi
show
low
respons
dose
fig
highest
respons
observ
pgml
ipv
du
du
group
respect
contrast
ipv
du
group
observ
signific
increas
cytokin
particular
week
post
vaccin
led
strong
induct
pgml
versu
pgml
ipv
du
group
pgml
versu
ipv
group
week
post
vaccin
ipv
alon
group
observ
increas
secret
cytokin
pgml
ipv
du
mice
pgml
ipv
group
pgml
ipv
mice
pgml
mice
ipv
du
observ
increas
pgml
pgml
signific
p
decreas
secret
compar
week
post
vaccin
thu
week
major
secret
cytokin
observ
group
strongest
respons
observ
group
fig
taken
togeth
use
induc
faster
stronger
cellular
respons
compar
nonadjuv
ipv
interestingli
cytokin
profil
group
chang
week
week
resembl
profil
similar
profil
induc
ipv
alon
fig
shed
polio
viru
consid
princip
marker
protect
studi
implic
intestin
iga
one
effector
mechan
reduc
shed
viru
therefor
examin
differ
vaccin
strategi
aim
gener
intestin
iga
specif
previou
experi
indic
intraderm
vaccin
administr
may
induc
intestin
iga
decid
first
compar
intramuscular
im
intraderm
id
administr
first
examin
iga
product
intestin
two
week
follow
two
vaccin
either
ipv
du
given
either
id
im
avoid
risk
blood
contamin
intestin
sampl
examin
fecal
pellet
taken
colon
sacrif
anim
neither
administr
form
induc
intestin
iga
fig
contrast
vaccin
strategi
induc
igg
serum
im
administr
highest
igg
induc
fig
correl
well
serum
neutral
titer
fig
thu
induc
signific
increas
titer
compar
ipv
id
group
ipv
im
group
observ
viru
serotyp
furthermor
id
administr
gave
reduc
bind
neutral
titer
compar
im
administr
suggest
id
administr
less
effici
prime
protect
humor
immun
respons
compar
im
administr
next
decid
test
strategi
combin
im
administr
id
administr
practic
import
anim
receiv
vaccin
im
id
dose
contrast
two
individu
formul
vaccin
booster
vaccin
mice
given
im
administr
anoth
idim
coadministr
data
shown
result
show
supplement
id
administr
im
administr
first
vaccin
induc
strong
increas
iga
titer
fece
fig
contrast
observ
increas
fecal
igg
level
fig
next
examin
idim
administr
also
affect
system
humor
cellular
respons
week
post
final
vaccin
anim
sacrif
blood
analyz
igg
bind
titer
neutral
titer
cellular
immun
igg
titer
adjuv
group
increas
compar
nonadjuv
ipv
group
reach
level
compar
ipv
du
group
fig
cellular
immun
measur
elisa
supernat
pbmc
stimul
ipv
vitro
result
show
respons
ipv
du
idim
group
high
pgml
ipv
du
im
group
pgml
significantli
higher
nonadjuv
group
fig
final
neutral
titer
ipv
du
idim
group
high
sera
ipv
du
im
group
significantli
higher
nonadjuv
ipv
du
group
fig
observ
serotyp
type
versu
type
versu
type
versu
fact
titer
ipv
du
idim
group
even
significantli
higher
titer
ipv
du
group
demonstr
dose
spare
effect
ipv
du
idim
group
taken
togeth
compar
im
administr
side
side
idim
administr
adjuv
vaccin
follow
im
administr
neg
affect
system
immun
measur
antibodi
bind
neutral
titer
cell
secret
fig
importantli
contrast
ipv
du
id
ipv
du
im
group
ipv
du
idim
group
observ
signific
increas
fecal
iga
wherea
fecal
igg
observ
either
vaccin
group
idim
group
receiv
twice
antigen
amount
first
vaccin
also
test
group
receiv
two
im
vaccin
time
two
differ
site
howev
lead
fecal
iga
data
shown
final
observ
signific
advers
effect
id
site
administr
well
known
prerequisit
worldwid
replac
opv
ipv
avail
afford
ipv
low
middleincom
countri
lower
cost
option
pursu
includ
reduc
number
dose
amount
antigen
per
dose
addit
lower
manufactur
cost
ipv
develop
countri
prioriti
result
show
adjuv
abl
achiev
time
dose
spare
effect
mice
measur
viru
neutral
titer
blood
fig
importantli
result
also
show
two
vaccin
ipv
du
gave
neutral
titer
either
equal
induc
vaccin
ipv
du
type
titer
slightli
reduc
type
titer
fig
thu
addit
adjuv
induc
signific
dose
spare
effect
allow
vaccin
schedul
one
less
dose
potenti
appli
two
vaccin
compar
three
signific
econom
practic
impact
present
ipv
vaccin
schedul
involv
dose
commonli
administ
week
month
recent
report
conclud
children
resourcepoor
set
probabl
protect
paralyt
poliomyel
two
dose
ipv
primari
vaccin
studi
base
ipv
vaccin
given
month
ie
matern
transfer
antibodi
declin
consequ
expect
inhibit
ipv
vaccin
addit
children
receiv
previou
opv
vaccin
protect
singl
ipv
dose
probabl
due
boost
promin
opv
induc
memori
b
cell
respons
thu
least
booster
vaccin
studi
indic
one
two
vaccin
protect
children
resourcepoor
set
paralyt
poliomyel
result
indic
inclus
adjuv
affect
requir
dose
allow
reduc
ipv
dose
number
vaccin
allow
vaccin
schedul
less
vaccin
dose
requir
induc
proper
protect
infect
polio
viru
respons
ipv
sever
vaccin
highli
sensit
matern
antibodi
level
significantli
lower
rate
seroconvers
three
polioviru
type
studi
perform
thailand
type
oman
studi
includ
babi
birth
week
onward
children
baselin
matern
antibodi
titr
addit
previou
studi
shown
ipv
appear
sensit
opv
effect
high
matern
antibodi
titer
reduc
neutral
antibodi
respons
vaccin
given
first
month
life
howev
previou
studi
highlight
two
import
point
concern
antibodi
respons
ipv
one
studi
show
matern
antibodi
inhibit
vaccineinduc
antibodi
respons
cell
respons
latter
allow
high
antibodi
titer
follow
booster
vaccin
addit
krishnan
et
al
show
neg
effect
matern
antibodi
respons
ipv
may
reduc
increas
interv
dose
taken
togeth
combin
result
suggest
inclus
adjuv
combin
booster
vaccin
given
longer
interv
commonli
use
week
eg
week
propos
previous
reduct
ipv
vaccin
dose
inde
feasibl
even
presenc
matern
antibodi
also
character
influenc
immun
respons
ipv
firstli
antibodi
bind
titer
week
post
vaccin
increas
level
case
higher
level
induc
time
higher
ipv
dose
du
fig
observ
three
polio
viru
type
fig
interestingli
contrast
observ
minor
respons
adjuv
nonadjuv
group
fig
contrast
previou
observ
adjuv
formul
recombin
protein
show
strong
respons
suggest
even
presenc
strong
adjuv
ipv
influenc
igg
respons
igg
isotyp
profil
vaccin
resembl
ipv
alon
suggest
ipv
determin
igg
profil
even
presenc
increas
antibodi
respons
induc
also
correl
increas
cellular
respons
measur
multiplex
cytokin
analysi
although
cellular
immun
respons
consid
direct
correl
protect
polio
vaccin
may
play
indirect
role
support
memori
b
cell
respons
analysi
antiipv
cell
immun
reveal
induc
faster
stronger
respons
ipv
week
post
vaccin
minor
respons
observ
nonadjuv
ipv
group
contrast
group
show
increas
level
cytokin
test
fig
adjuv
group
also
show
elev
cytokin
respons
week
post
vaccin
interestingli
result
also
show
cytokin
profil
group
chang
significantli
week
week
resembl
profil
induc
ipv
alon
profil
domin
secret
fig
indic
ipv
antigen
also
influenc
type
cellular
immun
induc
furthermor
known
induc
isotyp
switch
result
also
explain
observ
induct
lack
thu
regard
igg
respons
cellular
cell
respons
role
formul
ipv
induc
respons
quantit
differ
respons
induc
ipv
qualit
differ
observ
cell
profil
present
studi
agreement
previou
studi
show
cytokin
profil
follow
immun
sabin
ipv
alum
interestingli
studi
also
demonstr
cell
requir
protect
polio
infect
probabl
act
helper
cell
b
cell
stimul
neutral
antibodi
product
type
addit
cell
also
shown
requir
gener
optim
antibodi
respons
follow
infect
coronaviru
vaccinia
viru
yellow
fever
viru
vesicular
stomat
viru
vsv
support
role
cell
viral
infect
polio
viru
underestim
specul
cell
immun
mediat
express
cell
may
import
protect
polio
viru
due
abil
induc
isotyp
switch
induc
innat
immun
contribut
antivir
immun
accept
major
port
entri
polio
viru
intestin
tract
fecal
iga
import
prevent
entri
pathogen
therefor
induc
intestin
iga
prioriti
polio
vaccin
sever
public
indic
immunolog
connect
intraderm
intestin
site
howev
human
result
obtain
id
administr
ipv
entir
clear
thu
one
largescal
pediatr
studi
conduct
cuba
initi
vaccin
research
fail
meet
noninferior
criteria
wherea
anoth
show
three
immun
onefifth
dose
ipv
given
id
result
similar
seroconvers
rate
compar
three
full
dose
ipv
given
im
infant
although
antibodi
significantli
lower
infant
given
decreas
id
dose
ipv
thu
use
id
administr
rout
ipv
still
debat
result
present
paper
indic
inject
site
prime
immun
respons
intraderm
administr
effici
im
administr
mice
base
experi
show
reduc
bindingneutr
titer
id
group
compar
im
group
receiv
vaccin
fig
addit
id
administr
induc
iga
intestin
fecal
sampl
fig
data
shown
howev
compar
im
id
alon
administr
sidebysid
idim
administr
adjuv
vaccin
follow
im
administr
induc
signific
level
fecal
iga
import
without
compromis
serum
bind
neutral
titer
although
subject
futur
investig
may
suggest
cell
prime
system
recruit
site
eg
intestin
act
helper
cell
potenti
respons
site
may
import
suggest
strong
intestin
prime
may
entir
requir
intestin
protect
long
intestin
challeng
effect
boost
preexist
minor
intestin
immun
andor
lead
fast
recruit
immun
resid
system
locat
fact
respect
particular
interest
studi
shown
ipv
administ
via
im
rout
may
inde
prime
substanti
protect
intestin
immun
furthermor
tropic
develop
countri
supplement
dose
ipv
administ
children
previous
expos
opv
boost
humor
intestin
immun
effect
supplement
dose
opv
support
studi
perform
netherland
thu
seem
reason
assum
im
vaccin
ipv
induc
immun
abil
interact
intestin
site
simultan
prime
im
id
site
vaccin
increas
intestin
respons
conclus
first
time
character
formul
ipv
adjuv
formul
prove
constitut
stabl
formul
major
ipv
associ
maintain
dunit
activ
induc
strong
system
protect
immun
mice
also
influenc
kinet
ipv
immun
respons
produc
faster
respons
final
simultan
prime
intraderm
intramuscular
site
vaccin
led
intestin
immun
success
complet
sever
phase
studi
vaccin
candid
studi
ongo
support
develop
toward
human
trial
